Applications published 18 March 2009

Phosphoris containing compounds including triphenyl-methylphosphonate esters for the treatment of melanoma and other cancers
Board of Trustees of the University of Illinois 2034828*

Pharmaceutical compsn comprising cyclobenzaprine and aceclofenac in association
Incrementa PD&I Pesquisa, Desenvolvimento e Inovocao de Farmacos e Medicamentos 2034829*

Methods of treating stroke
Biogen Idec 2034830*

Alcohol-containing antimicrobial compsns having improved efficacy
The Dial Corporation 2034831*

IL-8 receptor antagonist
SmithKline Beecham 2034832*

Polynucleotide therapy
Bayhill Therapeutics 2034833*

Prodrugs of 5-amino-3-(3"-deoxy-beta-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-one
Anadys Pharmaceuticals 2034834*

Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
Summa Health System 2034835*

Novel compounds
Glaxo Group 2034838*

Treatment of neurodegenerative disease through inhibition of HSP90
Sloan-Kettering Institute for Cancer Research; The Rockefeller University 2034839*

Unit dose form of glufosfamide
Threshold Pharmaceuticals 2034950*

Rehydratable pharmaceutical product
Biocompatibles UK 2034951*

Aprepitant compsns
Dr Reddy's Laboratories Ltd; Dr Reddy's Laboratories Inc 2034952*

Orally disintegrating layered compsn
Capricom Pharma 2035953*

Non-viral compsns and methods for transfecting gut cells in vivo
Engene; Hsu, Eric 2034954*

Collagen scaffolds, medical implants with same and methods of use
University of South Florida; Shriners Hospital for Children 2034955*

Compsns comprising glycosaminoglycans of low viscosity and use of said compsn in therapy of chronic cystitis
Altergon 2034956*

Pharmaceutical compsn for oral adminstration
Pliva-Lachema 2034957*

Stable aqueous suspension having palatable taste
Norbrook Laboratories 2034958*

Optimised fluorocarbon emulsions for blood substitutes and other therapeutic uses
Alliance Pharmaceuticals 2034959*

Pharmaceutical compsns with biological barriers permeation enhancing properties
Carli, Fabio 2034960*

Solubilisate formulations
Langhoff, Gertrud 2034961*

Vesicular formulations containing organic acid prodrugs and process for their preparation
Universidade de Lisboa 2034962*

Gel-formulations of hydrophobic photosensitisers for mucosal applications
CeramOptec 2034963*

Process for producing nanoparticles by spray drying
Kerkhof, Nicholas 2034964*

Process for preparing a solid dosage form
Universiteit Gent 2034965*

A stabilised compsn comprising ACE inhibitors
Alphapharm 2034966*

Oral pharmaceutical compsn of a poorly water-soluble active substance
Solvay Pharmaceuticals 2034967*

Galenical formulations of aliskiren and hydrochlorothiazide
Novartis 2034968*

Immediate-release tablet formulations of a thrombin receptor antagonist
Schering 2034969*

Sustained release pharmaceutical formulation comprising phenylephrine
Schering-Plough Healthcare Products 2034970*

Steroid-containing sustained release intraocular implants and related methods
Allergan 2034971*

Enteric coated particles containing an active ingredient
McNeil-PPC 2034972*

Encapsulated labile compound compsns and methods of making the same
Martel Biosciences 2034973*

Lipoic acid pellets
Eurand Pharmaceuticals; Laboratorio Chimico Internationale 2034974*

Pharmaceutical compsns
Alpharma 2034975*

Delivery device having self-assembling dendritic polymers and method of use thereof
TTI Ellebeau 2034976*

• Use of opioid receptor antagonists
DSM 2034977*

• Organic compounds
Novartis 2034978*

• Treatment of cnidaria intoxication with vanilloid receptor antagonists
Katholieke Universiteit Leuven; University of Hawaii 2034979*

• Methods and compsns for the treatment of viral infections
Adamas Pharmaceuticals 2034980*

• Diamidine inhibitors of TDP1
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 2034981*

• Compsn for foodstuff for binding acetaldehyde
Biohit 2034982*

• Use of a polyunsaturated fatty acid compound
Lipid Nutrition 2034983*

• Method of treating atrophic vaginitis
Pear Tree Women's Health Care 2034984*

• Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins
Universite de la Mediterranee; Association Francaise Contre Les Myopathies; Assistance Publique Hopitaux de Marseille 2034985*

• High dose oral pharmaceutical compsns of artemether and lumefantrine
Ranbaxy Laboratories 2034986*

• New use for cannabinoid
GW Pharma 2034987*

• Compsns and kits comprising a melatonin component and a flavanol component
Procter & Gamble 2034988*

• Methods and compsns for improving cognitive function
Mars 2034989*

• Nebulisable compsns of quaternary ammonium muscarinic receptor antagonists
Dey 2034990*

• Preparation for preventing ageing symptoms containing phytoestrogens and melatonin
IR Med 2034991*

• Method of improved diuresis in individuals with impaired renal function
Novacardia 2034992*

• Pyrazinones as cellular proliferation inhibitors
EI du Pont de Nemours 2034993*

• NF-kappa B inhibitors and uses thereof
The Board of Trustees Operating Michigan State University 2034994*

• Method for treating proliferative disorders associated with protooncogene products
Synta Pharmaceuticals 2034995*

• Triazole compounds that modulate HSP90 activity
Synta Pharmaceuticals 2034996*

• Antibacterial compsns
Prolysis 2034997*

• 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors
Janssen Pharmaceutica 2034998*

• DHA esters and use thereof in treatment and prevention of cardiovascular disease
Pierre Fabre Medicament 2034999*

• HIF hydroxylase inhibitors for treatment of anaemia of cancer
Fibrogen 2035000*

• Stable laquinimod preparations
Teva Pharmaceutical Industries 2035001*

• Combination preparations comprising SLV308 and a L-dopa
Solvay Pharmaceuticals 2035002*

• A method of reducing amyloid-beta peptide levels using a bisdioxopiperazine
The Govt of the USA, as represented by the Secretary, Department of Health and Human Services 2035003*

• Phenyl substituted pyrazinoyl-guanidine sodium channel blockers possessing beta agonist activity
Parion Sciences 2035004*